New drug approvals for branded drugs, generics, plus OTCs, home health care, health and beauty, etc.
NEW DOSAGE STRENGTHS
Inspire Pharmaceuticals, Durham, N.C., (919) 941-9777, along with its partner InSite Vision, Alameda, Calif., have announced the U.S. launch and commercial availability of AzaSite (azithromycin ophthalmic solution) 1%. The product is said to offer the fewest number of doses for treating bacterial conjunctivitis (pinkeye) compared with other medications on the market.
Teva Pharmaceuticals, North Wales, Pa., has been granted final approval to market pantoprazole sodium delayed-release (DR) tablets, a generic version of Wyeth's Protonix. The tablets, available in 20 mg and 40 mg, are indicated for the short-term treatment of esophagitis associated with gastroesophageal reflux disease (GERD), maintenance of healing of erosive esophagitis, and treatment of hypersecretory conditions. The company can be reached at (888) TEVA USA.